The OmniScan ™ X4 128:128PR* enables the tackling of complicated tasks with confidence while remaining portable and lightweight. The ability to create new PAUT applications using 128-element pulsers.
X4 Pharmaceuticals announced the validation of its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome, by the European Medicines Agency (EMA). This rare primary ...
X4 Pharmaceuticals announced a restructuring to enhance operational efficiency and focus on advancing mavorixafor for chronic neutropenia while optimizing the promotion of XOLREMDI® for WHIM syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback